Hein W R, Harrison G B L
AgReseach Limited, Wallaceville Animal Research Centre, Ward Street, Upper Hutt, New Zealand.
Vet Parasitol. 2005 Sep 30;132(3-4):217-22. doi: 10.1016/j.vetpar.2005.07.006.
The majority of attempts to develop commercial vaccines for veterinary helminths have focussed on identifying protein antigens, which could be formulated as protective vaccines. Notable successes have been achieved for some cestode parasites, where recombinant proteins have been developed into highly effective vaccines. Although effective protection can also be obtained using some nematode proteins in their native forms, it has not yet been possible to formulate commercially successful vaccines for other helminth parasites of veterinary significance. Increasing evidence suggests that parasite glycan moieties may provide an alternative source of vaccine antigens, and increased attention is now being given to this class of compounds. In addition to identifying candidate protective antigen(s), an increased research effort is needed to develop appropriate strategies for the formulation and delivery of helminth vaccines.
开发兽用蠕虫商业疫苗的大多数尝试都集中在鉴定蛋白质抗原上，这些抗原可被制成保护性疫苗。对于一些绦虫寄生虫已取得显著成功，其中重组蛋白已被开发成高效疫苗。虽然使用一些天然形式的线虫蛋白也能获得有效保护，但尚未能够为其他具有兽医意义的蠕虫寄生虫研制出商业上成功的疫苗。越来越多的证据表明，寄生虫聚糖部分可能提供疫苗抗原的替代来源，现在人们对这类化合物的关注日益增加。除了鉴定候选保护性抗原外，还需要加大研究力度，以制定合适的蠕虫疫苗配方和递送策略。
